New drug combo tested for Hard-to-Treat blood cancers
NCT ID NCT04734990
Summary
This study is testing a new oral drug, seclidemstat, combined with an existing drug, azacitidine, for adults with certain advanced blood cancers (MDS and CMML) that have not responded well to prior treatment. The main goals are to find the safest and most effective dose of the new combination and to see if it can help control the cancer. Patients will take the drugs in repeating 28-day cycles and be monitored for side effects and how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.